摘要
目的:探讨聚乙二醇干扰素α-2a联合利巴韦林及双环醇治疗慢性丙型肝炎(慢性丙肝)的临床效果。方法:按照数字随机分组法将50例基因1型慢性丙肝患者随机分为实验组和对照组,实验组给予聚乙二醇干扰素α-2a联合利巴韦林、双环醇治疗,对照组给予聚乙二醇干扰素α-2a联合利巴韦林治疗,比较两组治疗期间肝功能改善状况、丙型肝炎病毒应答率以及不良反应发生情况。结果:治疗后第4、12、24周肝功能[总胆红素(TBIL)、谷丙转氨酶(ALT)、谷草转氨酶(AST)]复常率实验组均明显优于对照组,差异均有统计学意义(P<0.05)。两组HCV RNA应答率比较,快速病毒学应答(RVR)、早期病毒学应答(EVR)、完全早期病毒学应答(e EVR)、持续病毒应答率(SVR)实验组明显优于对照组36%vs.8%、80%vs.52%、68%vs.40%,差异均有统计学意义(P<0.05)。治疗期间两组不良反应发生情况比较,差异无统计学意义(P>0.05)。结论:在聚乙二醇干扰素α-2a联合利巴韦林治疗基础上加用双环醇治疗慢性丙肝,可明显改善患者肝功能、提高丙型肝炎病毒应答率。
Objective ： To explore the curative effects of peg-interferon α-2a plus ribavirin and bicyclol in patients with chronic hepatitis C （HCV）. Methods： Fifty patients with HCV were randomly divided into experimental group and control group. The experiment group was treated by peg-interferon a-2a plus ribavirin and bicyelol, and the control group was treated by peg-interferon α-2a plus ribavirin. The improvement of liver function, the response rates in the patients with HCV and side effects during therapy were compared between the two groups. Results： Liver function recovery rate at 4,12 and 24 weeks after the treatment were significantly better in the experimental group than those in the control group （ P 〈 0. 05 ）. The response rates such as RVR, EVR, eEVR and SVR were higher in the experimental group than those in the control group （36% vs. 8% , 80% vs. 52% ,68% vs. 40% , P 〈 0.05 ）. There were no statistically significant differences in the side effects between Peg-interferon α-2a plus ribavirin and bicyclol can improve the liver function and HCV RNA in patients with chronic hepatitis C. the two increase groups. Conclusion： the response rates to
出处
《现代医学》
2017年第5期641-644,共4页
Modern Medical Journal
基金
2012年江苏省南京市卫生局科研立项项目(YKK12115)
